File(s) under permanent embargo
Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
Methods: The Australian MS Longitudinal Study collected data from participants on DMTs usage from 2010 to 2015 and whether DMTs contributed to changes in employment outcomes. We classified 11 DMTs into three categories based on their clinical efficacy (β-interferons and glatiramer acetate as category 1; teriflunomide and dimethyl fumarate as category 2; fingolimod, natalizumab, alemtuzumab and mitoxantrone as category 3). Each DMT used by a participant was treated as one observation and analysed by log-multinomial regression.
Results: Of the 874 participants included, 1384 observations were generated. Those who used category 3 (higher efficacy) DMTs were 2-3 times more likely to report improvements in amount of work, work attendance and work productivity compared with those who used category 1 (classical injectable) DMTs. Natalizumab was associated with superior beneficial effects on patient-reported employment outcomes than fingolimod (RR=1.76, 95% CI 1.02 to 3.03 for increased work attendance and RR=1.46, 95% CI 1.02 to 2.10 for increased work productivity).
Conclusions: Those using the higher efficacy (category 3) DMTs, particularly fingolimod and natalizumab, reported significant increases in amount of work, work attendance and work productivity, suggesting they have important beneficial effects on work life in people with MS.
History
Publication title
Journal of Neurology, Neurosurgery and PsychiatryVolume
89Issue
11Pagination
1200-1207ISSN
0022-3050Department/School
Menzies Institute for Medical ResearchPublisher
B M J Publishing GroupPlace of publication
British Med Assoc House, Tavistock Square, London, England, Wc1H 9JrRights statement
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018.Repository Status
- Restricted